Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Consensus Price Target of $20.50

Key Points

• Analysts maintain a moderately bullish outlook: Telix Pharmaceuticals has a consensus “Moderate Buy” rating from five analysts, with an average 12-month price target of $20.50.
• Recent research actions included buy or outperform ratings from Citigroup, HC Wainwright, RBC, and Wedbush, while HC Wainwright and Wedbush set price targets of $20 and $22, respectively.
• Shares opened at $9.54, down 4.9%, compared with a 52-week range of $6.28 to $13.11. Several institutional investors recently increased or initiated positions in the company.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $20.50.

TLX has been the topic of several research reports. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, August 21st. Citigroup restated a "buy" rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Friday, September 25th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research note on Monday, September 21st. Finally, Wedbush reiterated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. WoodTrust Financial Corp bought a new stake in shares of Telix Pharmaceuticals in the 3rd quarter valued at $186,000. XY Capital Ltd lifted its holdings in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company's stock worth $822,000 after acquiring an additional 58,739 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the second quarter worth about $1,731,000. Bank of America Corp DE grew its stake in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock valued at $96,000 after acquiring an additional 8,423 shares during the period. Finally, Lazard Asset Management LLC grew its stake in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock valued at $2,775,000 after acquiring an additional 39,400 shares during the period.

Telix Pharmaceuticals Trading Down 4.9%

Shares of TLX stock opened at $9.54 on Friday. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $13.11. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The stock's fifty day moving average is $11.39 and its 200-day moving average is $10.79.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company's principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.